Jane Street Group, LLC Myovant Sciences Ltd. Call Options Transaction History

Jane Street Group, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	BUY	$11.38 - $16.4 $75,108 - $108,239	6,600 Added 30.41%	28,300 $377,000
Q3 2021 Nov 16, 2021	SELL	$18.94 - $26.99 $312,510 - $445,335	-16,500 Reduced 43.19%	21,700 $487,000
Q2 2021 Aug 16, 2021	BUY	$17.07 - $24.56 $114,369 - $164,552	6,700 Added 21.27%	38,200 $870,000
Q1 2021 May 18, 2021	SELL	$20.46 - $25.18 $2.06 Million - $2.53 Million	-100,600 Reduced 76.15%	31,500 $648,000
Q4 2020 Feb 17, 2021	BUY	$13.8 - $27.62 $1.13 Million - $2.27 Million	82,200 Added 164.73%	132,100 $3.65 Million

Q3 2020 Nov 17, 2020	SELL	$14.05 - $22.6 $465,055 - $748,060	-33,100 Reduced 39.88%	49,900 $701,000
Q2 2020 Aug 17, 2020	BUY	$7.34 - $20.84 $609,220 - $1.73 Million	83,000 New	83,000 $1.71 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.